This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
by Zacks Equity Research
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
BIIBPositive Net Change LLYPositive Net Change PRTAPositive Net Change SAVANegative Net Change
biotechs medical pharmaceuticals
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
by Zacks Equity Research
Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.
ANIPNegative Net Change WVEPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
by Zacks Equity Research
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.
REGNPositive Net Change RHHBYPositive Net Change AMGNPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
by Zacks Equity Research
The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.
ANIPNegative Net Change BHVNPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechs
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
by Zacks Equity Research
Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.
SNYPositive Net Change NVOPositive Net Change LLYPositive Net Change VTYXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
by Zacks Equity Research
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change
biotechnology biotechs pharmaceuticals
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
by Zacks Equity Research
APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.
ILMNPositive Net Change KRYSNegative Net Change APLSPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
by Zacks Equity Research
Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change CRBPNegative Net Change
biotechnology biotechs medical pharmaceuticals
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
by Zacks Equity Research
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
by Zacks Equity Research
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
REGNPositive Net Change SNYPositive Net Change BMYPositive Net Change JNJPositive Net Change
biotechs medical pharmaceuticals
Longboard Stock Soars on FDA Designations for Epilepsy Drug
by Zacks Equity Research
The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.
ILMNPositive Net Change KRYSNegative Net Change BVSPositive Net Change
biotechs medical
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
by Zacks Equity Research
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
AZNPositive Net Change JNJPositive Net Change ILMNPositive Net Change KRYSNegative Net Change
biotechs medical pharmaceuticals
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
by Zacks Equity Research
The FDA issues a complete response letter to Vanda's new drug application for tradipitant for treating symptoms in gastroparesis.
ILMNPositive Net Change VNDANegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechs
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
by Zacks Equity Research
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.
GSKPositive Net Change ILMNPositive Net Change KRYSNegative Net Change BVSPositive Net Change
biotechs medical pharmaceuticals vaccines
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
by Sundeep Ganoria
BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises.
JNJPositive Net Change MDTPositive Net Change BVSPositive Net Change
biotechs medical
EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies
by Zacks Equity Research
Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.
ILMNPositive Net Change KRYSNegative Net Change FULCPositive Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA
by Zacks Equity Research
Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia.
ILMNPositive Net Change KRYSNegative Net Change APLTPositive Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
by Zacks Equity Research
Gilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates.
REGNPositive Net Change GILDNegative Net Change MRNAPositive Net Change ZNTLPositive Net Change NUVLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
by Zacks Equity Research
The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.
RHHBYPositive Net Change BMYPositive Net Change PFEPositive Net Change NUVLNegative Net Change
biotechs medical pharmaceuticals
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?
by Ekta Bagri
ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
GRFSNegative Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Stock Rises 15% in 3 Months: Time to Add to Your Portfolio?
by Zacks Equity Research
ZTS' innovative pet care products, along with efforts to expand the business, are expected to fuel significant growth in the future.
ILMNPositive Net Change ZTSPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises
by Zacks Equity Research
Rocket completes enrollment of patients in a pivotal phase II study evaluating RP-A501 for treating male patients with Danon disease.
ILMNPositive Net Change RCKTPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechs
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
by Zacks Equity Research
ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.
BMRNNegative Net Change ILMNPositive Net Change ASNDPositive Net Change BVSPositive Net Change
biotechs medical pharmaceuticals
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
by Zacks Equity Research
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
NVSPositive Net Change PFEPositive Net Change LLYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals